comparemela.com

Pd 1 L1 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

China s Hengrui launches Luzsana with Big Pharma veterans

With a unique operating model, the Hengrui subsidiary aims to “quantifiably reduce costs” of medicines, its CEO said.

Jiangsu hengrui medicineLuzsana biotechnologyDrug pricesPd 1 l1Market accessMarket access strategiesAntibody drug conjugatesFierce pharma homepage

Fierce Pharma Asia—Takeda s patent cliff and rare disease setback; FDA s censure of Sun, Aurobindo

Takeda is preparing for the patent loss of its third-largest product but called it quits on a rare disease therapy.

Fierce pharma asiaSun pharmaceuticalAurobindo pharmaPatent lossesForm 483Alzheimer 039s diseaseJiangsu hengrui medicinePd 1 l1Merck kgaaTaiho pharmaceuticalFierce pharma homepage

Astellas, BeiGene, Serum Institute—Fierce Pharma Asia

Astellas takes gene therapy hit. Novartis and BeiGene post PD-1 win. Serum Institute halts COVID vaccine production.

Fierce pharma asiaCell amp gene therapyPd 1 l1Uchenne muscular dystrophy dmdSerum institute of indiaCovid 19Vaccine manufacturingPatent lawsuitsWuxi apptecFierce pharma homepage

Fierce Pharma Asia—FDA oncology czar on China PD-1 rebuff; US Senate s supply chain bill; Insilico s AI targets

Richard Pazdur, M.D., director of the FDA's Oncology Center of Excellence, defended the agency's rejection of Eli Lilly and Innovent Biologics' PD-1 inhibitor. The U.S.

Richard pazdurPd 1 l1Supply chainFierce pharma asiaEli lillyInsilico medicineSfda inspectionOno pharmaceuticalImmuno oncologyHalozyme therapeuticsSubcutaneous drug deliveryAurobindo pharmaM amp aWerner baumannRare diseasesSun pharmaceutical

As Lilly, Innovent hit FDA rebuff, another China-made PD-1 cancer drug faces possible delay

After the FDA snubbed Eli Lilly and Innovent Biologics’ cancer immunotherapy sintilimab because of China-only data, all eyes have turned to the next China-developed PD-1 therapy in line at the FDA.

Junshi biosciencesPd 1 l1Head and neck cancerImmuno oncologySfda inspectionInnovent biologicsCheckpoint inhibitorsFierce pharma homepage

vimarsana © 2020. All Rights Reserved.